“Do no harm” builds a bias against preventive medicine into medical practice, says Aubrey de Grey
“Do no harm” builds a bias against preventive medicine into medical practice, says Aubrey de Grey
On November 18, aging researcher Aubrey de Grey told the Ageless Athlete podcast that the principle of “do no harm” defines harm as making a healthy person ill. He argues for quantifying the risks and benefits of drugs and developing drugs against aging as quickly as COVID-19 vaccines.
Preventive medicine is a hard sell to the public, de Grey explains: people struggle to reason about uncertainty and fixate on the tiny chance that a drug will make a healthy person ill, overlooking the much greater likelihood that it will protect them from disease. Few preventive drugs exist, he says, and those that do entered medical practice “through the back door.” Cholesterol-lowering statins first proved beneficial in patients with heart disease and were only later used for prevention. Meanwhile, people are buying GLP-1 drugs such as Ozempic in large numbers to treat obesity, although he believes these drugs also protect against age-related conditions.
Prevention is also a hard sell to doctors. De Grey bases his argument on the principle of “first, do no harm,” which he traces to Hippocrates:
“‘First, do no harm’ amounts to saying ‘preventive medicine is a bad idea.’ That is because you can only harm someone who is not already ill: harm is defined as making someone ill, giving them a disease they did not already have. And you cannot remove a disease from someone who does not have it. You cannot have a negative number of diseases.”
Hippocrates probably did not mean “do no good,” the host objected. “He meant: do not try to do good if there is any chance that you might inadvertently do harm,” de Grey replied. This is the first principle taught in medical school, he says, creating “an enormous bias in the medical profession against preventive medicine, even though everyone knows it is exactly what we want.” People expect a drug to bypass the period when it is new and its effects are uncertain and to be safe from the outset, he says, but everything remains new for a time.
COVID-19 was different, he says: governments “swept aside and tore up all the regulatory inertia and bureaucratic delays.” Vaccines were developed and tested in less than a year; the previous speed record was about four years for the mumps vaccine in the 1960s. He acknowledges that corners were cut and side effects occurred, but says that the number of people saved far exceeded the number harmed. His conclusion: “There needs to be a proper quantitative assessment of risks and benefits. By and large, that simply does not happen.”
His forecast depends on the same rules: he puts the probability at 50% that by 2040, in 12–15 years, medicine will reach longevity escape velocity, the point at which each year of medical progress adds more than a year to people's life expectancy. Critics counter that a single drug takes 15 years to get through the FDA. De Grey replies: “My timelines assume that we will completely discard everything we think we know about how to conduct clinical trials, as we did with COVID.” For that to happen, society needs to tackle aging as soon as possible, “even if there are side effects.”
He hopes to spur the public to act through celebrities such as podcaster Joe Rogan and Kim Kardashian. To avoid risking their reputations, they need experts to tell them that it is time to act. He expects mice to convince the experts: if the combination of treatments against aging being tested by his LEV Foundation adds 8–12 months to the animals' lives, scientists will begin offering timelines as he does. The foundation's first experiment ended in 2025: four treatments were not enough to achieve the required increase in lifespan.